Ionis Pharmaceuticals (MEX:IONS) Defensive Interval Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:IONS Ionis Pharmaceuticals Inc MEX:IONS
72 GF Score
Price MXN1,150.00
GF Value MXN1,062.74
! 6 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Defensive Interval Ratio?

MEX:IONS
72GF Score
Ionis Pharmaceuticals Inc MEX:IONS
Defensive Interval Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ionis Pharmaceuticals (MEX:IONS) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,150.00 is trading 8.2% above its estimated GF Value™ of MXN1,062.74.

Key valuation signals for MEX:IONS:

  • Defensive Interval Ratio:
  • GF Value™: MXN1,062.74 vs. price of MXN1,150.00 (8.2% above fair value)
  • GF Score™: 72/100 with 6 warning signs

No single metric tells the full story. See the MEX:IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ionis Pharmaceuticals Business Description

Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
72GF Score

Get the complete analysis for MEX:IONS

Defensive Interval Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,150.00
Price
MXN1,062.74
GF Value